Publications

Population PK and Exposure-Response Modeling to Support the Design of Trials with DEBIO 0123, a WEE1 Inhibitor, in Cancer Patients

Results of a Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors –…

Exploring the content and psychometric validity of clinical outcome assessments in pancreatic ductal adenocarcinoma versus the patient reported symptoms and…

Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and…

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Gofabicin – A new FabI-inhibitor targeting antibiotic-resistant Neisseria gonorrhoeae​

Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer

A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a…

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase…